Objective: The usefulness of 2 novel biomarkers in pancreatic surgical and cytological specimens that could reliably differentiate non-neoplastic pancreatic duct and benign gut epithelium from pancreatic ductal adenocarcinoma (PDA) was evaluated. Study Design: A total of 14 pancreatic resection specimens (RSs), 23 endoscopic ultrasound-guided fine needle aspirations (EUS-FNAs) of PDA and 8 benign pancreatic EUS-FNAs were selected. Twelve of 14 RSs had corresponding EUS-FNAs with cell blocks (CBs). Non-neoplastic pancreatic tissue, including chronic pancreatitis, was evaluated in all RSs. Immunohistochemical stains for S100P and X-linked inhibitor of apoptosis protein (XIAP) were performed on tissue and CB sections. Staining intensity (0 no staining; 1+ weak; 2+ moderate; 3+ strong) and proportion of positive cells (less than 10% negative; 1+ 10–25%; 2+ 26–75%; 3+ greater than 75%) were assessed. Positive staining was defined as ≧10% cells with at least 1+ intensity. Results: The sensitivity and specificity of S100P and XIAP immunoreactivity for a diagnosis of PDA in RSs were both 100%. In contrast, the sensitivity and specificity in EUS-FNA CBs of S100P were 78.2 and 87.5% and of XIAP 82.6 and 50.0%, respectively. The combined sensitivity of S100P and XIAP was 100% in 12 RSs and 83.3% in the corresponding EUS-FNA CBs. Conclusion: Two novel biomarkers have very high sensitivity and specificity in the diagnosis of PDA in RSs. S100P has slightly lower sensitivity and higher specificity of PDA than XIAP in EUS-FNA specimens. We recommend using both biomarkers as cytological diagnostic adjuncts, especially in difficult cases of well-differentiated PDA versus reactive ductal epithelium.

1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–249.
2.
Yantiss RK, Cosar E, Fischer AH: Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas. Acta Cytol 2008;52:133–138.
3.
Yantiss RK, Woda BA, Fanger GR, et al: KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol 2005;29:188–195.
4.
Awadallah NS, Shroyer KR, Langer DA, et al: Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas 2008;36:200–206.
5.
Nawgiri RS, Nagie JA, Wilbur DC, Pitman MB: Cytomorphology and B72.3 labeling of benign and malignant ductal epithelium in pancreatic lesions compared to gastrointestinal epithelium. Diagn Cytopathol 2007;35:300–305.
6.
Deng H, Shi J, Wilkerson M, Meschter S, Dupree W, Lin F: Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens. Am J Clin Pathol 2008;129:81–88.
7.
Agarwal B, Ludwig OJ, Collins BT, Cortese C: Immunostaining as an adjunct to cytology for diagnosis of pancreatic adenocarcinoma. Clin Gastroenterol Hepatol 2008;6:1425–1431.
8.
Bhanot U, Heydrich R, Möller P, Hasel C: Survivin expression in pancreatic intraepithelial neoplasia (PanIN): steady increase along the developmental stages of pancreatic ductal adenocarcinoma. Am J Surg Pathol 2006;30:754–759.
9.
Awadalah NS, Dehn D, Shah RJ, et al: NQO1 expression in pancreatic cancer and its potential use as a biomarker. Appl Immunohistochem Mol Morphol 2008;16:24–31.
10.
Karanjawala ZE, Illei PB, Ashfaq R, et al: New markers of pancreatic cancer identified through differential gene expression analysis: Claudin 18 and Annexin A8. Am J Surg Pathol 2008;32:188–196.
11.
Chhieng DC, Benson E, Eltoum I, et al: MUC1 and MUC2 expression in pancreatic ductal adenocarcinoma obtained by fine-needle aspiration. Cancer Cytopathol 2003;99:365–371.
12.
Tascilar M, Offerhaus GJA, Altink R, et al: Immunohistochemical labeling for the Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct. Am J Clin Pathol 2001;116:831–837.
13.
Biankin AV, Morey AL, Lee CS, et al: DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol 2002;20:4351–4542.
14.
Wu M, Yuan S, Szporn AH, Gan L, Shtilbans V, Burstein DE: Immunocytochemical detection of XAIP in body cavity effusions and washes. Mod Pathol 2005;18:1618–1622.
15.
Hanley KZ, Facik MS, Bourne PA, et al: Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Cancer 2007;114:49–56.
16.
McCarthy DM, Maitra A, Argani P, et al: Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increase accuracy in cytologically borderline cases. Appl Immunohistochem Mol Morphol 2003;11:238–243.
17.
Arumugam T, Simeone DM, VanGolen K, Logsdon CD: S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res 2005;11:5356–5364.
18.
Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R, et al: Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am J Pathol 2005;166:81–91.
19.
Sato N, Fukushima N, Matsubayashi H, Goggins M: Identification of mapsin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene 2004;23:1531–1538.
20.
Guerreiro Da Silva ID, Hu YF, Russo IH, et al: S100P calcium-binding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages breast cancer development in vivo. Int J Oncol 2000;16:231–240.
21.
Beer DG, Kardia SL, Huang CC, et al: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816–824.
22.
Bertram J, Palfner K, Hiddenmann W, Kneba M: Elevated expression of S100P, CAPL and MAGE3 in doxorubicin-resistant cell lines: comparison of mRNA differential display reverse transcription-polymerase chain reaction and subtractive suppressive hybridization for the analysis of differential gene expression. Anticancer Drugs 1998;9:311–317.
23.
Amler LC, Agus DB, LeDuc C, et al: Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res 2000;60:6134–6141.
24.
Crnogorac-Jurcevic T, Missiaglia E, Blaveri E, et al: Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol 2003;201:63–74.
25.
Holcik M, Korneluk RG: XAIP, the guardian angel. Nat Rev Mol Cell Biol 2001;2:550–556.
26.
Mizutani Y, Nakanishi H, Li YN, et al: Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol 2007;30:919–925.
27.
Lopes RB, Gangeswaren R, McNeish IA, Wang Y, Lemoine NR: Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. Int J Cancer 2007;120:2344–2352.
28.
Li Y, Jian Z, Xia K, et al: XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics. Pancreas 2006;32:288–296.
29.
Lin F, Staerkel G: Cytologic criteria for well differentiated adenocarcinoma of the pancreas in fine-needle aspiration biopsy specimens. Cancer 2003;99:44–50.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.